Nusano Expands Executive Team for Future Success
Nusano, Inc., a pioneering company at the forefront of medical radioisotope production, is making strategic enhancements to its executive team as it gears up for an exciting phase of commercialization scheduled for 2025. Based in Valencia, California, Nusano is focused on revolutionizing the availability of non-carrier-added lutetium-177, also known as n.c.a. Lu-177.
New Executives Join Nusano's Vision
The recent addition of two key executives marks a significant step forward for Nusano. Kevin Haehl assumes the role of Chief Product Officer, and Jzaneen Lalani takes on the position of Chief Business Officer. Their diverse backgrounds and extensive experience bring fresh perspectives that will propel Nusano toward its pivotal upcoming goals.
Introduction of Kevin Haehl
Kevin Haehl brings over 35 years of experience in the biotechnology and pharmaceutical manufacturing sectors. Previously the Chief Development Officer at Nucleus Radiopharma, Haehl has successfully led various site development initiatives and played a crucial role in the company's financial growth. At Nusano, his focus will encompass driving product and supply chain operations, ensuring employee health and safety, and fostering the growth of Nusano's technical and scientific teams.
Role of Jzaneen Lalani
Jzaneen Lalani adds over two decades of experience across multiple life sciences disciplines. Prior to her new role as Chief Business Officer, she served as a business consultant to Nusano since early 2023. In her new capacity, Lalani will oversee human resources, legal matters, government relations, and special projects, including the construction of Nusano’s innovative radioisotope production facility in Utah.
Promotions Within Nusano
Alongside the new hires, Nusano announced the promotion of Rohan Jain to Chief Commercial Officer from his previous position as Commercial General Manager. Moreover, Chris Ignace has been promoted to Senior Vice President of Scientific Affairs from VP of Regulatory Affairs and Quality Assurance. These changes highlight Nusano's commitment to cultivating leadership from within the organization.
Importance of Medical Radioisotopes
Medical radioisotopes are critical components in modern cancer therapies, serving as the active pharmaceutical ingredients in many new treatments. As the demand for these resources continues to rise, the existing supply chains often face challenges, risking patient care and the progression of clinical trials. Nusano’s commitment to supplying high-quality medical radioisotopes is essential in meeting the needs of drug manufacturers, hospitals, and clinics, allowing them to create vital treatment options for patients.
Future Production Goals
Nusano's future production plans are highly ambitious. The company intends to produce non-carrier-added lutetium-177 through a proprietary radiochemistry separation process, beginning in 2025. Following this, production of actinium-225 is set to commence at its state-of-the-art facility in Utah by 2026. This pipeline aims to ensure a stable supply of critical medical isotopes, which are vital in the fight against cancer.
About Nusano
Nusano is a privately held company dedicated to supplying innovative radioisotope solutions to an undersupplied market. With advanced proprietary technologies, Nusano is poised to contribute significantly to cancer treatment by increasing the availability and quality of much-needed medical radioisotopes. The company’s innovative production platform aims to produce isotopes in a variety and volume unmatched by traditional methods.
Frequently Asked Questions
What is Nusano, Inc.?
Nusano, Inc. is a company specializing in the production of medical radioisotopes for cancer treatment and research.
Who are the new executives joining Nusano?
The new executives are Kevin Haehl, Chief Product Officer, and Jzaneen Lalani, Chief Business Officer.
What are the key goals for Nusano in 2025?
Nusano plans to begin the production of non-carrier-added lutetium-177 and launch its production platform in Utah.
Why are medical radioisotopes important?
Medical radioisotopes are crucial for developing new cancer therapies and improving patient care.
What is the future production plan for Nusano?
Nusano aims to produce n.c.a. lutetium-177 in 2025 and actinium-225 in 2026 at its facility in Utah.